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Abstract
Background: The most common pituitary adenoma presentation is a 
visual field defect and inappropriate pituitary hormone secretion. The 
compression of the optic chiasm causes visual impairment. Large pituitary 
adenomas can rarely cause diplopia and ptosis secondary to adenoma’s 
lateral extension into the cavernous sinus. Myasthenia gravis is an 
autoimmune disorder involving neuromuscular junctions. It is characterised 
by skeletal muscle fatigability, commonly involving extraocular muscles, 
face and limbs. It is estimated that 75% of myasthenia gravis patients 
present with ptosis and diplopia. The association of myasthenia gravis 
with pituitary adenoma is very rare. Case Description: A 30-year-old lady 
presented with headache, diplopia and ptosis of the left eye for 2 months. 
She was diagnosed with acromegaly secondary to pituitary adenoma. 
Ptosis is a rare presenting feature in pituitary adenoma. Her case was 
discussed in a multidisciplinary meeting, and the consensus was that her 
ptosis is likely secondary to pituitary adenoma, which was involving the 
left cavernous sinus. She underwent transsphenoidal resection of pituitary 
macroadenoma. Three weeks post-surgery, she developed bilateral ptosis, 
dysarthria and dysphonia, which was diagnosed as myasthenia gravis. 
Clinical Implications: Ptosis is a rare manifestation of pituitary adenoma. 
Nonetheless, pituitary tumour patients presenting with ptosis should be 
evaluated for the neuromuscular disorder. A high index of suspicion is 
required for early diagnosis and prompt treatment of myasthenia gravis.
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Introduction
Myasthenia gravis is an autoimmune condition 
of neuromuscular junctions. Two specific 
antibodies directed against post-synaptic nicotinic 
acetylcholine receptor and anti-muscle-specific 
tyrosine kinase antibody at the neuromuscular 
junction causes signal transmission impairment. 
The hallmark of myasthenia gravis is off and 
on fatigability of skeletal muscles, including 
extraocular, face, limbs and thoracic muscles, 
which worsen with muscle activity. Double vision 
and ptosis are the presenting complaints in almost 
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Pituitary adenoma comprises 15–20% of all 
primary intracranial tumours.[4,5] Somatotroph 
adenomas are growth hormone-producing 
pituitary adenomas, resulting in gigantism in 
younger patients and acromegaly in adults. 
Neuro-ophthalmological manifestations present 
in 10% of pituitary adenoma cases due to close 
anatomical proximity of the pituitary gland, optic 
chiasm and the cranial nerves in the cavernous 
sinus.[6] The classic ophthalmologic presentation 
is visual field defects, with bitemporal hemianopia 
being most commonly reported.[7] Oculomotor (3rd) 
nerve palsy is a rare but possible presentation of 
pituitary adenoma due to its lateral extension into 
the cavernous sinus.[8,9]
The presence of both pituitary adenoma and 
myasthenia gravis in a patient at the same time 
is rare. There are only a handful of case reports 
describing growth hormone-secreting pituitary 
adenoma and myasthenia gravis presenting 
simultaneously in a patient.[10,11] This study was 
exempted from taking informed consent by the 
local Institutional Review Board.
Case Description
A 30-year-old lady presented with 2 months 
history of headache, diplopia and ptosis of the left 
eye. Her periods were regular, with no history of 
spontaneous galactorrhoea. She had no significant 
medical history. She had four children, and the 
youngest child was 2 years old. All pregnancies 
were uneventful.
The clinical findings demonstrated prominent 
supraorbital ridges, macroglossia, prognathism 
and partial ptosis on the left side. Both of the pupils 
were equal in size and reactive to light. Her visual 
fields could not be clinically assessed due to the 
presence of ptosis.
She underwent radiological and laboratory 
investigations, including magnetic resonance 
imaging (MRI) pituitary, insulin-like growth factor-1 
(IGF-1), prolactin, FSH, LH, morning cortisol (9 am-
cortisol), TSH, free T4 and fasting glucose.
The MRI pituitary showed a pituitary mass measuring 
around 23 mm × 14 mm × 24 mm, causing the 
displacement of the pituitary stalk and partially 
extending into the parasellar region encircling the 
left internal carotid artery and compressing the 
left cavernous sinus [Figure 1]. There was no optic 
chiasm compression or hydrocephalus.
Her laboratory tests revealed markedly raised IGF-1 
of 1073 ng/mL (normal range: 71–234 ng/mL) and 
marginally elevated prolactin of 35.1 ng/ml (normal 
range: 1.90–25 ng/mL). Other pituitary hormones 
were within normal ranges.
Her case was discussed in a multidisciplinary tumour 
board (MDT) meeting comprising endocrinologists, 
neuroradiologists, pathologists, clinical radiation-
oncologists and neurosurgeons. The consensus 
was that the patient had acromegaly, and her 
unilateral ptosis was secondary to compression of 
the left oculomotor nerve by the pituitary adenoma.
She underwent transsphenoidal resection of 
pituitary adenoma. The perioperative period was 
uneventful. The histopathology of the excised tissue 
was consistent with growth hormone-secreting 
pituitary adenoma.
Three weeks after surgery, she developed complete 
bilateral ptosis. In addition, she had difficulty in 
eating, dysarthria and dysphonia. Her neurological 
examination revealed muscle fatigability. Her anti-
acetylcholine receptor antibodies were positive.
Diagnosis and management
Based on the dramatic development of bilateral 
ptosis post-surgically, along with symptoms of 
difficulty in eating, dysarthria and dysphonia, 
clinical signs of muscle fatigability and positive anti-
acetylcholine receptor antibodies test, a diagnosis 
of myasthenia gravis was made.
The patient was started on prednisolone 20 mg 
daily and pyridostigmine 90 mg daily (in divided 
doses) and had an excellent clinical response. The 
patient remained well on the treatment, except 
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for weight gain, which was likely secondary to the 
corticosteroids. At her 6 months follow-up in the 
endocrine clinic post-surgery, her IGF-1 levels 
were 552 ng/mL (normal range: 71–234 ng/mL). 
The post-operative MRI pituitary showed a residual 
pituitary mass of 13 mm × 9 mm × 11 mm involving 
the left cavernous sinus [Figure 2].
Eight months after the diagnosis of myasthenia 
gravis, the patient presented to the emergency 
department with a 2-day history of decreased 
consciousness, shortness of breath and the 
inability to eat and communicate. Her arterial 
blood test showed type II respiratory failure. The 
family reported that the patient had stopped her 
medications due to weight gain, which lead to the 
diagnosis of myasthenia crisis. The patient was 
admitted to intensive care, where over 2 weeks, 
she had multiple plasmapheresis sessions.
During her stay, she had computed tomography 
(CT) thorax, which revealed thymic enlargement. 
She underwent video-assisted thoracoscopy 
and subsequently a radical thymectomy. The 
histopathology of the excised tissue was consistent 
with thymic hyperplasia.
At 21 months post-surgery follow-up, her IGF-1 
level remained raised (321 ng/mL [normal range: 
71–234 ng/ml]), oral glucose tolerance test failed 
to suppress growth hormone and the MRI pituitary 
revealed a stable residual pituitary mass involving 
the left cavernous sinus. Her myasthenia gravis 
symptoms were well controlled on azathioprine 
50 mg 3 times daily and pyridostigmine 60 mg 
3 times daily, and the patient was no longer on 
corticosteroids.
Her case was rediscussed in the MDT meeting, and 
the board suggested that the patient undergoes 
radiation therapy or somatostatin analogue. The 
patient opted for radiation therapy due to financial 
constraints. She is due to receive radiation therapy.
Discussion
Pituitary macroadenoma with extension into the 
lateral wall of the cavernous sinus can disrupt the 
Figure 1: Post-contrast coronal (a), axial (b) and sagittal (c) images of magnetic resonance imaging (MRI) pituitary 
show heterogeneously enhancing pituitary macroadenoma encasing the left internal carotid artery and causing mass 
effect on the cavernous sinus (white arrows)
cba
Figure 2: Post-contrast T1 (a) and pre-contrast T2 
(b)  coronal images of magnetic resonance imaging 
pituitary showing residual soft tissue involving the left 
cavernous sinus (blue arrows)
ba
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third, fourth and sixth cranial nerve. In this patient, 
the MRI study suggested that the adenoma was 
extending into the lateral wall of the cavernous 
sinus. However, due to the inherent limitation of 
the MRI study, the exact involvement of which 
specific cranial nerve was impacted could not 
be established. However, clinically patient had 
ipsilateral ptosis, which was suggestive of the 
third cranial nerve involvement.[12] The patient 
underwent transsphenoidal resection of pituitary 
adenoma.
Her myasthenia gravis must have been present at 
a very early stage at the time of her presentation. 
She had delivered her youngest child 2 years 
ago, without any neurological complications. 
Similarly, she had partial unilateral ptosis without 
any other neurological features. This assumption 
was further supported by the absence of any 
post-operative neurological complications after 
pituitary surgery. Many factors can precipitate 
a myasthenia crisis, including a concurrent 
infection, surgical intervention, pregnancy, 
childbirth or tapering of immunosuppressive 
medications.[13-15] Perioperative management of 
patients with myasthenia gravis requires careful 
thought and planning.[16] All these features make 
it very difficult to diagnose myasthenia gravis 
early during the course of the disease. The 
close proximity of pituitary macroadenoma with 
the third cranial nerve further complicated the 
perplexity of this clinical situation. Nonetheless, 
bilateral ptosis development a few weeks post-
surgery prompted consideration for other possible 
explanations for her symptoms. The subsequent 
clinical assessments and laboratory investigations 
confirmed the diagnosis of myasthenia gravis.
The four accepted modalities for the treatment of 
myasthenia gravis include symptomatic treatment 
with an acetylcholinesterase inhibitor, such as 
pyridostigmine and neostigmine, intravenous 
immunoglobulin or plasma exchange, which 
provides a rapid but transient clinical improvement, 
immunosuppressive therapy consisting of 
corticosteroids, azathioprine, mycophenolate 
mofetil, cyclosporine and methotrexate and 
thymectomy, which may provide therapeutic relief 
in selected patients.[17,18] 
There is evidence in the literature to support a 
correlation between the immune system and the 
neuroendocrine system.[19-22] The growth hormone 
has been shown to promote the proliferation of 
different cells, including chondrocytes, fibroblasts, 
adipocytes, myoblasts and T lymphocytes. 
Similarly, studies exhibit deficiencies in lymphocyte 
development and function in hypophysectomised 
animals, which responded partially to exogenous 
growth hormone administration. Moreover, the 
replacement of growth hormone was found to 
enhance the development of the thymus in aged 
mice and promote the engraftment of human T 
cells in mice.[20,21] Furthermore, thymic atrophy 
has been observed with ablation of the pituitary 
gland.[22]
This case highlights the importance of a thorough 
history and clinical assessment. The association 
of ptosis without any other clinical neurological 
symptoms with pituitary adenomas is uncommon. 
Patients with ptosis without any other neurological 
signs and suspicious pituitary adenomas should 
undergo assessment for myasthenia gravis to avoid 
potentially severe consequences with post-surgical 
complications.
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